Consistent with previous reports, vemurafenib treatment enhanced ERBB3 expression and improved the sensitivity of melanoma cells to ERBB3 ligand, NRG1, as assessed by the phosphorylation of AKT (Fig. 7a). The gene discussed is ERBB3; the disease is melanoma.